Download Global Cancer Antibody Drug Conjugates Market and Pipeline Insight 2022 Report

“Global Cancer Antibody Drug Conjugate Market and Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical parameters involved in the development of global cancer antibody drug conjugate market. In recent years antibody drug conjugates have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 243 antibody drug conjugates in clinical pipeline for the treatment of cancer. Majority of antibody drug conjugates for the treatment of cancer are in preclinical stage followed by research phase clinical trials. There are 6 cancer antibody drug conjugates commercially available in the market. Report helps to analyze the clinical pipeline of antibody drug conjugates by Company, Indication , Mode of Action, Formulation and Phase

Antibody drug conjugates have emerged as new addition to the cancer therapeutic segment which is already overcrowded and consists of numerous competitors. Antibody drug conjugates are based on monoclonal antibodies which delivers drugs in highly targeted manner. Their superior pharmacological profiles have allowed the pharmaceutical companies to commercialize them in highly competitive cancer segment.

Monoclonal antibodies have quite strong hold in cancer market due to high therapeutic efficacy along with minimized side effects. But, it was realized that pharmacological profiles of presently available monoclonal antibodies would not be able to offer benefits in future as cancerous cells develop resistance. Moreover, other benefits like remission, quality of life, morbidity, mortality rates and other parameters are modest at their best. Definitely, monoclonal antibodies are way superior as compared to their traditional counterparts but more improvement is required in order to offer better therapeutic effects. To overcome such issues, concept of antibody drug conjugates was developed; now this concept has been materialized due to availability of advanced technology.

For the cancer where validated predictive biomarkers are available, administration of targeted therapies such as antibody drug conjugates and others have been associated with unprecedented tumor response and clinical benefit. Efforts to design tolerable combination therapies involving antibody-drug conjugate, cancer vaccine, immune checkpoint and kinase inhibition are rational means of maximizing clinical benefit in the targeted delivery of anticancer therapies. The major advantage of using antibody drug conjugates is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the market in terms of targeted accumulation of drug in the tumor cell or tissue. Apart from this there are several other benefits of antibody drug conjugates which are driving the market and will be accelerating its share in the upcoming future.


“Global Cancer Antibody Drug Conjugate Market and Clinical Pipeline Insight 2022” report highlights:

Impetus of Antibody Drug Conjugates
Mechanism of Cancer Antibody Drug Conjugates
Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview
Marketed Cancer Antibody Drug Conjugate Clinical Insight
Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication , Mode of Action, Formulation and Phase

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-cancer-antibody-drug-conjugates-market-and-pipeline-insight-2022.php

Impetus of Antibody Drug Conjugates
1.1 Prologue to Cancer Antibody Drug Conjugate
1.2 The ABCs of ADCs

Structural Entities of Antibody Drug Conjugate
2.1 Rational Design of Antibody Drug Conjugates
2.1.1 Monoclonal Antibody
2.1.2 Linker
2.1.3 Drug Payload
2.2 Aspects of Conjugational Chemistry

Revolutionizing Antibody Drug Conjugates Generation
3.1 First and Second Generation ADCs
3.2 Third Generation ADCs

Mechanism of Cancer Antibody Drug Conjugates
4.1 Sequential Therapeutic Mechanism for Cancer
4.1.1 Selecting an Appropriate Target
4.1.2 Antigen Binding Complex
4.1.3 Antibody Drug Conjugate Internalization
4.2 Approved Antibody Drug Conjugate

Global Cancer Antibody Drug Conjugates Market Overview

Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview
6.1 Phase
6.2 Indication
6.3 Mechanism of Action
6.4 Company
6.5 Formulation

Global Cancer Antibody Drug Conjugates Market Dynamics
7.1 Favorable Market Parameters
7.2 Commercialization Challenges

Global Cancer Antibody Drug Conjugates Market Future Prospects
8.1 Approaching Newer Approaches
8.2 Upcoming Future Market Prospects

Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-II/III
9.8 Phase-III
9.9 Preregistration

Marketed Cancer Antibody Drug Conjugate Clinical Insight
10.1 Brentuximab Vedotin (Adcetris)
10.2 Mifamurtide (Junovan and Mepact)
10.3 Gemtuzumab Ozogamicin (Mylotarg)
10.4 Trastuzumab Emtansine (Kadcyla)
10.5 Ibritumomab Tiuxetan (Zevalin and Zevamab)
10.6 Satumomab (OncoScint CR/OV)

Competitive Landscape
11.1 AbbVie
11.2 AbGenomics Corporation
11.3 Biogen Idec
11.4 Biotest
11.5 Bristol-Myers Squibb
11.6 Celldex Therapeutics Inc
11.7 Helix BioPharma
11.8 IBC Pharmaceuticals
11.9 ImmunoGen
11.10 Immunomedics
11.11 Merck
11.12 Millennium
11.13 Nordic Nanovector
11.14 Novartis
11.15 PDL BioPharma
11.16 Progenics Pharmaceuticals
11.17 Roche
11.18 Seattle Genetics
11.19 Stem CentRx
11.20 UCB
11.21 Viventia Biotechnologies

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.